{"id":"nalfurafine","rwe":[{"pmid":"41902927","year":"2026","title":"Effects of repeated nalfurafine and VZTK35 treatments on fentanyl/cocaine mixture self-administration in a rat drug-vs.-food choice procedure.","finding":"","journal":"Psychopharmacology","studyType":"Clinical Study"},{"pmid":"41820058","year":"2026","title":"[Prevalence and influencing factors of chronic kidney disease-associated pruritus in patients undergoing maintenance hemodialysis].","finding":"","journal":"Zhonghua yi xue za zhi","studyType":"Clinical Study"},{"pmid":"41730054","year":"2006","title":"Nalfurafine.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"41616927","year":"2026","title":"Pain signaling via sensory neurons drives breast cancer progression through neuropeptide release and κ-opioid counter-regulation.","finding":"","journal":"Pharmacological research","studyType":"Clinical Study"},{"pmid":"41497575","year":"2025","title":"Genome-Wide Association Studies Data and Transcriptomics Data Link Herpes Simplex Virus 1 Infection and Parkinson's Disease.","finding":"","journal":"Parkinson's disease","studyType":"Clinical Study"}],"tags":[{"label":"nalfurafine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Kappa-type opioid receptor","category":"target"},{"label":"OPRK1","category":"gene"},{"label":"MAPK1","category":"gene"},{"label":"MAPK3","category":"gene"},{"label":"V03AX02","category":"atc"},{"label":"Active","category":"status"},{"label":"Severe Pruritus","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NALFURAFINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:54:00.447593+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:54:05.689888+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NALFURAFINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:54:06.313082+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL267495/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:07.017253+00:00"}},"allNames":"remitch","offLabel":[],"synonyms":["TRK-820","winfuran","remitch","nalfurafine","nalfurafine hydrochloride","nalfurafine HCl"],"timeline":[{"date":"2009-01-21","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"approvals":[{"date":"2009-01-21","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Remitch","ecosystem":[{"indication":"Severe Pruritus","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Kappa-type opioid receptor","targets":[{"gene":"OPRK1","source":"DrugCentral","target":"Kappa-type opioid receptor","protein":"Kappa-type opioid receptor"},{"gene":"MAPK1","source":"DrugCentral","target":"Mitogen-activated protein kinase 1","protein":"Mitogen-activated protein kinase 1"},{"gene":"MAPK3","source":"DrugCentral","target":"Mitogen-activated protein kinase 3","protein":"Mitogen-activated protein kinase 3"},{"gene":"OPRM1","source":"DrugCentral","target":"Mu-type opioid receptor","protein":"Mu-type opioid receptor"},{"gene":"OPRD1","source":"DrugCentral","target":"Delta-type opioid receptor","protein":"Delta-type opioid receptor"},{"gene":"OPRL1","source":"DrugCentral","target":"Nociceptin receptor","protein":"Nociceptin receptor"},{"gene":"HCRTR1","source":"DrugCentral","target":"Orexin receptor type 1","protein":"Orexin receptor type 1"}],"modality":"Small Molecule","drugClass":"nalfurafine","explanation":"","oneSentence":"","technicalDetail":"Remitch acts as a kappa opioid receptor agonist, binding to the kappa-type opioid receptor and activating G-protein coupled signaling pathways that ultimately lead to the reduction of itching."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4673","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NALFURAFINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NALFURAFINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:36:44.603291","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:08.791715+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cobicistat","drugSlug":"cobicistat","fdaApproval":"2012-08-27","patentExpiry":"Sep 3, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"difelikefalin","drugSlug":"difelikefalin","fdaApproval":"2021-08-23","patentExpiry":"Nov 12, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"nalfurafine","indications":{"approved":[{"name":"Severe Pruritus","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cobicistat","brandName":"cobicistat","genericName":"cobicistat","approvalYear":"2012","relationship":"same-class"},{"drugId":"difelikefalin","brandName":"difelikefalin","genericName":"difelikefalin","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07478133","phase":"NA","title":"Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans","status":"COMPLETED","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2023-05-24","conditions":["Pruritus"],"enrollment":72,"completionDate":"2023-07-14"},{"nctId":"NCT07380113","phase":"PHASE4","title":"Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-02-01","conditions":["Pruritus Chronic","Kidney Diseases, Chronic","Renal Insufficiency, Chronic","Uremia; Chronic","Pruritus Due to Systemic Disorder (Disorder)","Pruritus Due to Hemodialysis"],"enrollment":50,"completionDate":"2027-12-31"},{"nctId":"NCT07098351","phase":"NA","title":"Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-08-07","conditions":["Adverse Event","Peritoneal Dialysis","Moderate-to-severe Pruritus","Chronic Kidney Disease-associated Itch"],"enrollment":93,"completionDate":"2026-06-30"},{"nctId":"NCT01660243","phase":"PHASE2","title":"Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis","status":"TERMINATED","sponsor":"Toray Industries, Inc","startDate":"2012-09","conditions":["Uremic Pruritus"],"enrollment":45,"completionDate":"2014-03"},{"nctId":"NCT04728984","phase":"PHASE3","title":"A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet","status":"UNKNOWN","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2020-09-07","conditions":["Uremic Pruritus"],"enrollment":135,"completionDate":"2021-10-31"},{"nctId":"NCT02659696","phase":"","title":"Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Teikyo University","startDate":"2015-09","conditions":["Primary Biliary Cirrhosis"],"enrollment":44,"completionDate":"2018-03"},{"nctId":"NCT03002233","phase":"PHASE1","title":"TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus","status":"COMPLETED","sponsor":"Toray Industries, Inc","startDate":"2016-11","conditions":["Uremic Pruritus"],"enrollment":23,"completionDate":"2017-07"},{"nctId":"NCT01513161","phase":"PHASE3","title":"Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2008-04","conditions":["Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis"],"enrollment":104,"completionDate":"2009-10"},{"nctId":"NCT01248650","phase":"PHASE1","title":"Safety Study of TRK-820 for Patient With Hemodialysis","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2008-12","conditions":["Chronic Renal Failure"],"enrollment":16,"completionDate":"2008-12"},{"nctId":"NCT00793156","phase":"PHASE3","title":"A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)","status":"UNKNOWN","sponsor":"Acologix, Inc.","startDate":"2009-12","conditions":["Uremic Pruritus"],"enrollment":350,"completionDate":"2011-03"},{"nctId":"NCT00638495","phase":"PHASE2","title":"Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -","status":"COMPLETED","sponsor":"Toray Industries, Inc","startDate":"2008-03","conditions":["Pruritus With Chronic Liver Disease"],"enrollment":120,"completionDate":"2009-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"XC41AVD567","CHEBI":"CHEBI:136019","INN_ID":"8209","UMLSCUI":"C2825264","chemblId":"CHEMBL267495","ChEMBL_ID":"CHEMBL267495","KEGG_DRUG":"D06405","DRUGBANK_ID":"DB13471","PDB_CHEM_ID":" IVB","PUBCHEM_CID":"6445230","IUPHAR_LIGAND_ID":"1651","SECONDARY_CAS_RN":"152658-17-8","MESH_SUPPLEMENTAL_RECORD_UI":"C111212"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":173,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"V03AX02","allCodes":["V03AX02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 28","pmid":"41902927","title":"Effects of repeated nalfurafine and VZTK35 treatments on fentanyl/cocaine mixture self-administration in a rat drug-vs.-food choice procedure.","journal":"Psychopharmacology"},{"date":"2026 Mar 17","pmid":"41820058","title":"[Prevalence and influencing factors of chronic kidney disease-associated pruritus in patients undergoing maintenance hemodialysis].","journal":"Zhonghua yi xue za zhi"},{"date":"2006","pmid":"41730054","title":"Nalfurafine.","journal":""},{"date":"2026 Mar","pmid":"41616927","title":"Pain signaling via sensory neurons drives breast cancer progression through neuropeptide release and κ-opioid counter-regulation.","journal":"Pharmacological research"},{"date":"2025","pmid":"41497575","title":"Genome-Wide Association Studies Data and Transcriptomics Data Link Herpes Simplex Virus 1 Infection and Parkinson's Disease.","journal":"Parkinson's disease"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2009","aiSummary":"Remitch is a small molecule intervention used to study various conditions, including Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus, Chronic Kidney Disease-associated Itch, and Pruritus. Remitch, also known as Nalfurafine Hydrochloride Orally Disintegrating Tablets, has been studied for its efficacy and safety in treating moderate-to-severe pruritus in patients on peritoneal dialysis.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2009-01-21T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:08.791715+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}